Pharmacological Class and Classification
Omeprazole (Omeprazolum) belongs to drugs affecting the digestive system. It is a benchmark antisecretory agent — a medication that inhibits gastric acid secretion by parietal cells. Within this group, it represents the class of proton pump inhibitors ($H^+/K^+$-ATPase inhibitors). For context, antisecretory agents also include $H_2$ histamine receptor antagonists (e.g., cimetidine, famotidine) and antimuscarinics (e.g., atropine, pirenzepine).
Mechanism of Action and Pharmacodynamics
Chemically, the drug is a benzimidazole derivative. Its mechanism of action involves the irreversible blockade of the $H^+/K^+$-ATPase enzyme (the proton pump) on the membrane of gastric parietal cells.
The drug exhibits high efficacy: a single oral dose suppresses gastric acid secretion by more than 90% for 24 hours. Unlike antacids (such as algeldrate, magnesium carbonate, or sodium bicarbonate), which only temporarily (for 30–60 minutes) chemically neutralize acid already present in the gastric lumen, omeprazole blocks the very process of acid formation.
Indications for Use
The primary indication is the exacerbation of peptic ulcer disease.
The drug is also a critical agent for the prevention and management of NSAID-induced gastropathy. Nonsteroidal anti-inflammatory drugs cause non-receptor inhibition of COX-1, reducing the synthesis of protective prostaglandins ($PgE_2$, $PgI_2$) in the gastric wall. This creates an imbalance between aggressive and protective factors: acid secretion increases against the background of reduced mucus and bicarbonate production. This leads to mucosal ulceration and a high risk of gastrointestinal bleeding. Administering omeprazole (gastroprotection) effectively prevents this damage. Notably, attempting to wash down NSAIDs with milk is largely ineffective; milk only temporarily buffers acid and does not reverse the systemic suppression of prostaglandin synthesis.
Adverse Effects and Risks of Long-Term Therapy
Possible adverse effects include dyspepsia (nausea) and headache.
The main limitations relate to the duration of therapy. Treatment courses for acute ulcer exacerbations should not exceed 4–8 weeks. This is due to the "rebound" mechanism: prolonged achlorhydria (absence of acid) triggers a compensatory feedback increase in gastrin secretion. This leads to hyperplasia of enterochromaffin-like and parietal cells (observed in 10–20% of patients) and increases the risk of gastric mucosal atrophy.
Drug Interactions (Cytochrome P450)
Omeprazole actively interacts with the cytochrome P450 system, acting as both a substrate and an inducer/inhibitor of various isoenzymes:
- CYP1A2: Omeprazole acts as a pharmacological inducer of this isoenzyme (alongside phenobarbital and rifampin). This can accelerate the metabolism of substrates such as caffeine, theophylline, paracetamol, and warfarin. A dangerous risk of CYP1A2 and CYP1A1 induction is the bioactivation of carcinogens: certain environmental compounds become carcinogenic only after metabolic activation.
- CYP2C19: The drug is both a substrate and an inhibitor (auto-inhibition) of this isoenzyme. This creates a dangerous paradoxical effect when combined with prodrugs. For example, the antiplatelet agent clopidogrel requires activation via CYP2C19. Omeprazole blocks this enzyme, decreasing the concentration of clopidogrel's active metabolite, which leads to reduced antithrombotic efficacy and a high risk of thrombosis.
- CYP2D6: Omeprazole serves as a substrate for this isoenzyme (alongside codeine, haloperidol, and metoprolol).
Administration and Prescription Guidelines
The drug is administered orally in the morning before meals. The standard dose is 20 mg (0.02 g) once daily. An important rule: the capsule must be swallowed whole without damage (do not open or chew).
Prescription Example: Rp.: Caps. Omeprazoli 0.02 D.t.d. N. 20 S. Take orally in the morning before meals, 1 capsule once daily (swallow capsule intact).